Hydroxyurea Use Among Patients with Sickle Cell Disease (SCD): A Descriptive Analysis

    Basic Details
    Date Posted
    Tuesday, March 29, 2022
    Status
    Complete
    Medical Product
    hydroxyurea
    Description

    In this analysis, we characterized use of hydroxyurea among patients with sickle cell disease (SCD) in the Sentinel Distributed Database (SDD). This analysis contains two reports:

    • Report 1: We¬†described use of hydroxyurea among patients with SCD in the SDD. The study period includes data from January 1, 2000 to December 31, 2020. We distributed this request to seven Sentinel Data Partners on July 27, 2021.
    • Report 2:¬†We described patients with SCD who were and were not dispensed hydroxyurea, and estimated the number of hospitalizations and emergency department visits among those patients in the SDD. The study period includes data from January 1, 2000 to September 30, 2020. We distributed this request to seven Sentinel Data Partners on April 30, 2021.
    Additional Details
    FDA Center
    CDER
    Time Period
    January 1, 2000 - December 31, 2020; January 1, 2000 - September 30, 2020
    Study Type
    Modular Program
    Assessment Type
    Exploratory Analyses
    Population / Cohort
    All individuals
    Data Sources
    Sentinel Distributed Database (SDD)